Kevin Tan

Mr. Tan has served as the Chief Financial Officer of Solid Biosciences since January 2023.

From September 2021 to November 2022, Mr. Tan was Chief Financial Officer at Selecta Biosciences Inc., a biopharmaceutical company. While there, he led all financial functions, business development, corporate communications, and investor relations. From May 2018 to September 2021, Mr. Tan held positions of increasing responsibility at Sarepta Therapeutics, Inc., a precision genetic medicine company. He was a key member of the Business Development team and ultimately served as Treasurer of the organization. Prior to Sarepta, Kevin had a long career in financial services most recently as Senior Portfolio Manager at CPP Investments, the national pension fund of Canada. Prior to CPP Investments, Kevin worked in capital markets roles at Macquarie Capital and Lehman Brothers and in Mergers & Acquisitions at UBS Investment Bank.

Mr. Tan received a Bachelors of.Commerce from Queen’s University at Kingston, a Masters Degree in Engineering in Operations Research and Financial Engineering from Princeton University and an MBA from The University of Chicago Booth School of Business. Mr. Tan is a Chartered Financial Analyst.